Results 261 to 270 of about 3,422,852 (337)

High‐throughput microfluidic real‐time PCR as a promising tool in disease ecology

open access: yesJournal of Animal Ecology, EarlyView.
This work highlights the diversity of disease ecology questions Htrt PCR could contribute to addressing in a given host–pathogen ecosystem. This tool could be used to answer a broad set of basic and applied questions in animal ecology, notably by providing a way to address issues involving communities of hosts and communities of pathogens.
Tristan Bralet   +15 more
wiley   +1 more source

Dietary L-arabinose-induced gut dysbiosis exacerbates Salmonella infection outcome. [PDF]

open access: yesmSystems
Yu J   +9 more
europepmc   +1 more source

Multi‐omics reveal the gut microbiota‐mediated severe foraging environment adaption of small wild ruminants in the Three‐River‐Source National Park, China

open access: yesIntegrative Zoology, EarlyView.
This research reveals the gut microbiota‐mediated severe foraging environment adaptation of wild small ruminants in the Three‐River‐Source National Park. Unlike Tibetan sheep (TS), blue sheep (PN and Tibetan antelope (TA) often grazed low‐quality herbage in a wildness environment, and the higher microbial diversity and resilient network characteristics
Hongjin LIU   +11 more
wiley   +1 more source

Phylosymbiosis and Parallel Geographical Patterns in the Gut Microbiota of Desert‐Dwelling Amphibians and Reptiles

open access: yesIntegrative Zoology, EarlyView.
Host species emerge as a significant contributor to interspecies variations in the gut microbiota of desert‐dwelling amphibians and reptiles, illustrating phylosymbiosis among the studied species. Geographical factors partially account for interpopulation variations in the gut microbiota of Bufotes pewzowi and Teratoscincus przewalskii, with parallel ...
Wei Zhu   +8 more
wiley   +1 more source

Anti‐KIT Barzolvolimab for Chronic Spontaneous Urticaria

open access: yesAllergy, EarlyView.
We compared the efficacy and safety of four doses of barzolvolimab compared to placebo in reducing symptoms of chronic spontaneous urticaria in a randomized, controlled trial. Across barzolvolimab doses, rapid symptom reduction within 1 week was observed and sustained during 12 weeks.
Marcus Maurer   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy